Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ciprofloxacina

Ciproxin, Mediflox e altri

Bibliografia - Quali fonti bibliografiche per Ciprofloxacina?

  1. Abou-Auda H.S. et al., Biopharm. Drug Dispos., 2008, 29 (1), 29.

  2. Adverse drug reaction bulletin, 2000, 135, 539.

  3. Agenzia Italiana del Farmaco – AIFA, Nota informativa – Fluorochinoloni ad uso sistemico e inalatorio: rischio di aneurisma e dissezione dell’aorta, 2018, 26 ottobre https://www.aifa.gov.it/documents/20142/632048/Fluoroquinolones-DHPC_23.10.2018.pdf/696c1b7f-3fe9-d444-d52a-1a17d42ac15c (accesso: novembre 2019).

  4. Agenzia Italiana del Farmaco – AIFA, Nota informativa – Antibiotici chinolonici e fluorochinolinici per uso sistemico e inalatorio. Rischio di effetti indesiderati invalidanti, di lunga durata e potenzialmente permanenti e restrizioni d’uso, 2019, 8 aprile http://www.aifa.gov.it/content/nota-informativa-importante-su-medicinali-contenenti-fluorochinoloni-08042019.

  5. Akinleye M.O. et al., Nig. Q. J. Hosp. Med., 2007, 17 (1), 53.

  6. Avent C.K. et al., Am. J. Med., 1988, 85 (3), 452.

  7. Bauer L.A. et al., Antimicrob. Agents Chemother., 2005, 49 (4),1649.

  8. Bollettino d’Informazione sui Farmaci, 2009, 2, 81.

  9. Boesler B. et al., Z. Gastroenterol., 2009, 47 (5), 429.

  10. Brouwers E.E. et al., Clin. Drug Investig., 2009, 29 (1), 59.

  11. Carbon C., Drugs, 1993, 45 (Suppl. 3), 91.

  12. Chopra N. et al., J. Urol., 2000, 164, 438.

  13. Corrao G. et al., Drug Saf., 2006, 29, 889.

  14. Cox C.E., Am. J. Med., 1989, 87 (Suppl. 5A), 252S.

  15. Dalle J.H. et al., J. Pediatr. Hematol. Oncol., 2002, 24 (4), 321.

  16. Daneman N. et al., BMJ Open, 2015, 5 (11), e010077.

  17. Dellamonica P. et al., Eur. J. Microbiol. Infect Dis., 1989, 12, 1024.

  18. Deppermann K.M., Lode H., Drugs, 1993, 45 (Suppl.), 63.

  19. Doctor, 2002, 14, 18.

  20. Doctor, 2003, 5, 18.

  21. Drug Ther. Bull., 1994, 3, 77.

  22. Drug Ther. Bull., 1998, 4, 30.

  23. Dupont H.L., Drugs, 2006, 66, 303.

  24. European Medicines Agency – EMA, EMA/668915/2018, 2018, 5 ottobre https://www.ema.europa.eu/documents/press-release/fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use_en.pdf (accesso: ottobre 2018).

  25. European Medicines Agency – EMA, 2018a, EMA/795349/2018, 2018, 16 novembre.

  26. Fan-Harvard P. et al., Ann. Pharmacother., 1994, 28 (7-8), 869.

  27. Fass R.J., Antimicrob Agents Chemother., 1987, 31, 148.

  28. Food and Drug Administration – FDA, FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes, 2018, 10 luglio https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm (accesso: agosto 2018).

  29. Friedlander A.M. et al., J. Infect. Dis., 1993, 167, 1239.

  30. Friedman J., Polifka J., Teratogenic effects of drugs: a resource for clinicians (TERIS). Baltimore, Maryland: Johns Hopkins University Press, 2000, 149.

  31. Furet Y.X., Pechere J.C., Eur. J. Clin. Microbiol. Infect Dis., 1991, 10, 249.

  32. Garbis H. et al., Elsevier, 2001, 58.

  33. Grabe M. et al., Eur. J. Clin. Microbiol., 1987, 6, 11.

  34. Granfors M.T. et al., Clin. Pharmacol. Ther., 2004, 76 (6), 598.

  35. Grossaman A. et al., Drug Invest, 1994, 8 (2), 110.

  36. Haller I., Antimicr. Ag. Chem., 1985, 28, 663.

  37. Haller I., Arzneim-Forsch, 1986, 36, 226.

  38. Hedaya M.A. et al., Biopharm. Drug Dispos., 2006, 27 (2), 103.

  39. Herrlin K. et al., Lancet, 2000, 356 (9247), 2069.

  40. Hooper D.C., Wolfson J.S., N. Engl. J. Med., 1991, 324, 384.

  41. How P.P. et al., Clin. J. Am. Soc. Nephrol., 2007, 2 (6), 1235.

  42. Ilo C.E. et al., Am. J. Ther., 2008, 15 (5), 419.

  43. Informazioni sui farmaci, 2000, 4, 96.

  44. Informazioni sui farmaci, 2009, 4, 93.

  45. Iqbal Z. et al., Clin. Drug Investig., 2009, 29 (4), 275.

  46. Job M.L. et al., Ther. Drug Monitor., 1994, 16, 427.

  47. Jokinen M.J. et al., Eur. J. Clin. Pharmacol., 2003, 58 (10), 653.

  48. Kamali F. et al., Eur. J. Clin. Pharmacol., 1993, 44 (4), 365.

  49. Kaye C.M., Nicholls B., Clin. Pharmacokinet., 2000, 39 (4), 243.

  50. Kays M.B. et al., Am. J. Kidney Dis., 2003, 42 (6), 1253.

  51. Kehana L.M., Spino M., DICP Ann. Pharmacother., 1991, 25, 919.

  52. Kim J. et al., Drug Metab. Pharmacokinet., 2009, 24 (2), 167.

  53. Kim S.H. et al., Chemotherapy, 2009, 55 (4), 207.

  54. Kimura I. et al., Phytother. Res., 1999, 13 (6), 484.

  55. Klietmann W. et al., Arzneim-Forsch, 1987, 37, 661.

  56. Kloskowski T. et al., Pulm. Pharmacol. Ther., 2010, consultabile all’indirizzo:http://www.ncbi.nlm.nih.gov/pubmed/20211752

  57. Kushner J.M. et al., Ann. Pharmacother., 2001, 35, 1194.

  58. Labbé L., Turgeon J., Clin. Pharmacokinet., 1999, 37 (5), 361.

  59. Landersdorfer C.B. et al., Br. J. Clin. Pharmacol., 2010, 69 (2), 167.

  60. Lawrence J.W. et al., J. Cell. Biochem., 1993, 51, 165.

  61. Lee C.C. et al., JAMA Intern. Med., 2015, 175 (11), 1839.

  62. LeMaire S.A. et al., JAMA Surg. 2018, 153 (9), e181804.

  63. Lin G. et al., J. Toxicol. Clin. Toxicol., 2004, 42 (3), 295.

  64. Ljungberg B., Nilsson-Ehle I., Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8, 515.

  65. Loebstein R. et al., Antimic. Agents Chem., 1998, 42, 1336.

  66. Maggiolo F. et al., Drugs Exp. Clin. Res., 1991, 17 (9), 451.

  67. Marcelín-Jiménez G. et al., Clin. Drug Investig., 2006, 26 (6), 323.

  68. Marchbanks C.R., Pharmacotherapy, 1993, 13(2 Pt 2), 23S.

  69. McLellan R.A. et al., Drug Metab. Dispos., 1996, 24 (10),1134.

  70. Michael R. et al., J. Pharmacy Pharmacol., 1993, 45, 171.

  71. Muzi F. et al., Transplant Proc., 2007, 39, 1673.

  72. Nethwani D., Wood M.J., J. Hosp. Infect, 1992, 22, 181.

  73. Newsom S.W.B. et al., J. Antimicrob. Chemother., 1986, 18 (Supp. D), 111.

  74. Ohnishi M. et al., Biol. Pharm. Bull., 2009, 32 (6), 1080.

  75. Owens R.C. Jr., Drugs, 2004, 64 (10), 1091.

  76. Owens R.C. Jr, Nolin T.D., Clin. Infect. Dis., 2006, 43 (12), 1603.

  77. Pápai K. et al., J. Pharm. Biomed. Anal., 2010, 52 (1), 37.

  78. Pasternak B. et al., BMJ, 2018, 360, k678.

  79. Penning-van Beest F.J. et al., J. Thromb. Haemost., 2008, 6(2), 284.

  80. Polk R.E. et al., J. Antimicrob. Chemother., 1989, 33, 1841.

  81. Ponnusamy K. et al., Scand. J. Infect. Dis., 2010, consultabile all’indirizzo: http://www.ncbi.nlm.nih.gov/pubmed/20380543

  82. Raoul J.M. et al., Biochem. Pharmacol., 2007, 74 (4), 639.

  83. Sahai J. et al., Clin. Pharmacol. Ther., 1993, 53 (3), 292.

  84. Sawant R.D., Can. J. Clin. Pharmacol., 2009, 16 (1), e78.

  85. Schaefer C. et al., Eur. J. Obst. Gyn. Repr. Biol., 1996, 69, 83.

  86. Shalit I. et al., J. Antimicrob. Chemother., 1989, 33, 593.

  87. Sohn D.W. et al., Int. J. Antimicrob. Agents, 2009, 34 (3), 215.

  88. Sosntein S.A., Burnham J.C., Diagnostic Microbiol. Infect. Dis., 1993, 16, 227.

  89. Sv N. et al., Eur. J. Drug Metab. Pharmacokinet., 2003, 28 (4), 253.

  90. Tabak M. et al., FEMS Microbiol. Lett., 2009, 301 (1), 69.

  91. Tanimura H et al., Arzneim-Forsch., 1986, 36, 1417.

  92. Terp D.K., Rybay M.J., Drug Intell. Clin. Pharm., 1987, 21, 568.

  93. The Medical Letter, 1999, 22, 95.

  94. The Medical Letter, 2001, 23, 99.

  95. The Medical Letter, 2002, 10, 43.

  96. The Medical letter, 2008, 18, 71.

  97. Thys J.P. et al., Eur J. Clin. Microbiol. Infect. Dis., 1991, 10, 304.

  98. Vance-Bryan K. et al., Clin. Pharmacokinet., 1990, 19, 434.

  99. van den Berg F.P. et al., Ann. Vasc. Surg., 2010, consultabile all’indirizzo: http://www.ncbi.nlm.nih.gov/pubmed/19892516

  100. Varon E., Med. Mal. Infect., 2009, 39 (7-8), 432.

  101. Washington C. et al., Am. J. Health Syst. Pharm., 2006, 63 (7), 653.

  102. Washington C. et al., J. Clin. Pharmacol., 2007, 47 (10), 1320.

  103. Winstanley T.G. et al., J. Antimicrob. Chemother, 1997, 40, 591.